^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Mekinist (trametinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
Excerpt:
...- CRC must be KRAS or BRAF mutation positive....
Trial ID:
Source:
Title:
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
Excerpt:
...- Presence of KRAS gene mutation (at codon 12, 13, or 61) for patients on expansion cohort....
Trial ID:
Less C2 evidence
Source:
Title:
A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer
Excerpt:
...a robotics-based screen using this platform identified trametinib plus zoledronate as a candidate treatment combination. Treating the patient led to a significant response: Target and nontarget lesions displayed a strong partial response and remained stable for 11 months. By addressing a disease's genomic complexity, this personalized approach may provide an alternative treatment option for recalcitrant disease such as KRAS-mutant colorectal cancer.
Secondary therapy:
zoledronic acid
DOI:
10.1126/sciadv.aav6528
Source:
Title:
1056 / 11 - Determining efficacy of combining the MEK inhibitor trametinib with vincristine identified by unbiased high throughput screening in RAS-mutated colorectal cancer cells
Published date:
03/09/2022
Excerpt:
The efficacy of this combination was also examined in vivo using KRAS mutated patient derived xenografts (PDXs)....combining trametinib with vincristine led to significant inhibition in tumor growth when compared to the monotherapies using RAS-mutated PDXs in vivo.
Secondary therapy:
vincristine
